Frankfurt - Delayed Quote EUR

Unity Biotechnology, Inc. (9U90.F)

0.7100

-0.0840

(-10.58%)

As of 8:08:14 AM GMT+2. Market Open.

Bluebird pleads for deal support; Unity, Mersana lay off staff

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its workforce.

BioPharma Dive 8 days ago

MRSN

LLY

UBX
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST <400 microns (60% of enrolled patients) Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn SOUTH SAN FRANCISCO, Calif., May

GlobeNewswire 8 days ago

UBX
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the Company will present 36-week data from the ASPIRE Phase 2B study at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting being held on May 4-8, 2025 in Salt Lake City, Utah. ARVO 2025 Presentation Details: Title: Safety and Efficacy of Sen

GlobeNewswire 12 days ago

UBX
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, “Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema,” the results suggested

GlobeNewswire 20 days ago

UBX
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025. UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax) showed vision improvements

GlobeNewswire 21 days ago

UBX
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.

Zacks last month

UBX

REGN
Unity reports topline outcomes from trial of diabetic macular oedema therapy

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Clinical Trials Arena last month

UBX
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

GuruFocus.com last month

UBX
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior

GlobeNewswire last month

UBX
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here. The event will feature prominent ophthalmology key opinion leader (KOL) Robert Bhisitkul, MD, PhD from the UCSF School of Medicine, who will join company management t

GlobeNewswire last month

UBX
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company’s board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose experti

GlobeNewswire 2 months ago

UBX
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024. “We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “DME remains a significant

GlobeNewswire 2 months ago

UBX
UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that on January 6, 2025, the Compensation Committee of the Board of Directors (the “Board”) granted a stock-based award to a new employee, Federico Grossi, UNITY’s Chief Medical Officer, covering options to purchase 150,000 shares of UNITY common stock. The stock-based award w

GlobeNewswire 4 months ago

UBX
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVR

GlobeNewswire 4 months ago

UBX
We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

UBX
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024. “As recently discussed on our Ophthalmology Day for investors and analysts, diabetic macular edema represents a large underserved market due to inadequate response to anti-VEGF standard of care, continued vision los

GlobeNewswire 6 months ago

UBX
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

SAN FRANCISCO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that it will host an in-person and virtual event for investors and analysts on Tuesday, October 15, 2024, at 8:00 a.m. ET in New York, NY. The event will feature presentations from prominent ophthalmology key opinion leaders (KOLs) and company management. UNITY Biotechnology Ophthalmology D

GlobeNewswire 7 months ago

UBX
UNITY Biotechnology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following investor conferences. H.C. Wainwright 4th Annual Ophthalmology Virtual ConferencePresentation Date and Time: Thursday, August 15, 2024 at 7:00 a.m. ETLocation: V

GlobeNewswire 8 months ago

UBX
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know

UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 8 months ago

UBX
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024. “Having expanded and extended our ASPIRE study to 50 patients and 36 weeks, respectively, to better assess the efficacy and durability of UBX1325 compared to aflibercept, we have been laser-focused on enrollment and exe

GlobeNewswire 9 months ago

UBX

Performance Overview

Return	9U90.F	S&P 500 (^GSPC)
YTD	-27.25%	+0.08%
1-Year	-50.07%	+12.20%
3-Year	-90.95%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Unity Biotechnology, Inc. (9U90.F)

Bluebird pleads for deal support; Unity, Mersana lay off staff

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

Unity reports topline outcomes from trial of diabetic macular oedema therapy

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

UNITY Biotechnology Reports Granting of New Employment Inducement Award

UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer

We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024

UNITY Biotechnology to Participate in Upcoming Investor Conferences

UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

Performance Overview